We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Ligand Pharmaceuticals Incorporated (PK) | USOTC:LGNZZ | OTCMarkets | Right |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.109 | 0.10 | 0.13 | 0.00 | 13:34:01 |
Delaware
|
001-33093
|
77-0160744
|
(State or other jurisdiction of
|
(Commission File Number)
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification No.)
|
3911 Sorrento Valley Boulevard, Suite 110
|
|
92121
|
San Diego, CA
|
|
(Zip Code)
|
(Address of principal executive offices)
|
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Name and title
|
2019 Base Salary
|
2018 Bonus
|
John L. Higgins, Chief Executive Officer
|
$650,000
|
$517,615
|
Matthew W. Foehr, President and Chief Operating Officer
|
$490,000
|
$252,412
|
Matthew Korenberg, Executive Vice President, Finance and Chief Financial Officer
|
$470,000
|
$235,641
|
Charles S. Berkman, Senior Vice President, General Counsel and Secretary
|
$430,000
|
$177,100
|
|
LIGAND PHARMACEUTICALS INCORPORATED
|
Date: January 25, 2019
|
By:
/s/ Charles Berkman
Name: Charles Berkman
Title: Senior Vice President, General Counsel and Secretary
|
1 Year Ligand Pharmaceuticals (PK) Chart |
1 Month Ligand Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions